I wrote about this issue months ago - The shortage of ETO suppliers is stressing orthopedic device companies. Now we all get some more time.
PSA
I am writing this as public service announcement to those device companies still using EtO.
Use these 30 months wisely.
Dive into viable EtO swaps now, starting with pilot validations tailored to your orthopedic portfolio.
Below, I break down four promising paths, weighing their upsides and pitfalls with an eye on bone-and-joint applications.
Remember, early prototyping isn't optional—it's your safeguard against costly redesigns down the line.
Orthopedic device manufacturing's reliance on ethylene oxide (EtO) for sterilization has long been a double-edged sword. It's effective, but its environmental footprint has drawn sharp regulatory scrutiny.
For smaller companies—those nimble innovators often squeezed between big players and tight budgets—the pressure to pivot has been immense.
Enter a recent policy shift that's buying you precious time: President Donald Trump's July executive order, which pushes back the Environmental Protection Agency's (EPA) stringent EtO emission caps from an impossible 2026 timeline to April 2028.
This isn...
